Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Blackhawks, thanks. I was aware of these pages but one never knows what's hidden if you don't search thoroughly. What I am looking for is some language that indicates that the DOD and AMBS/Banyan are now researching MANF as a therapeutic in human subjects. The grant that seebisquick found indicates research for a biomarker but I don't think indicates any research of MANF.
The reason why this is important is that we all know that AMBS/Banyan have partnered in research of MANF as a therapeutic in TBI and that in vitro studies came back with exciting indications and confirmation of them. What we don't know, as of now, is that MANF is being studied in human beings. If DOD is funding such research it would be big news. As of now I'm dubious but searching.
Thanks! I've been looking all over the DOD engine with no luck.
Thanks. I thought about adding Watson's little nugget from this morning. Apparently the Banyan/AMBS collaborative study on MANF in TBI has gone into a large human trial funded by DOD. Apparently this is currently underway.
I can't confirm, but Watson says its Googleable. I haven't found it yet. But it would be nice to add this to the list soon.
Thanks DocStock,
I hope people are beginning to see the pattern...
1. NIH financed research of Lympro for TBI
2. DOD financed research of MANF for RP
3. MJFF funded research into MANF for PD
4. MJFF funded research into Eltropazine
There may be others I'm missing.
Pretty clever people working with powerful technology.
Question: how it is that little AMBS could pull off all this research, get a hold of all this mind-blowing medical technology, help get a world class conference at the UN together - all with virtually no cash? Why are all these doors opening for them?
This isn't about conspiracies, it's about understanding what AMBS's technology means and who's getting behind it.
Here's the link to an abstract of the DOD funded research on MANF in RP:
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=76ea053d-6fdd-4338-ac0b-66e2ff1885a1&cKey=a6522c99-616b-4978-8252-b8dff363a98e&mKey=f0fce029-9bf8-4e7c-b48e-9ff7711d4a0e
"Results: MANF significant protected rod photoreceptors. In MANF-treated retinas, three to four rows of nuclei remained in the outer nuclear layer (ONL), as compare to only one row of nuclei in PBS-treated fellow eyes. The thickness of ONL in MANF-treated retinas (superior region) (17.47±3.96 µm, mean±SD, n=5) is significantly greater than that in PBS-treated retinas (7.07±1.12, n=5) (P < 0.001, student t-test). Loss of cone outer segments was characterized by many PNA-negative areas distributed across the retina in PBS treated retinas, as reported previously,. In RdCVF treated eye, however, the PNA negative areas became much smaller or in many cases completely disappeared. Quantitative analysis showed that PNA-positive cells are significantly more in MANF treated retinas (569.5±46.5/0.1 mm2, mean±SD, n=6) than in PBS-treated retinas (398.7±25.4, n=6) (P< 0.001, student t-test).
Conclusions: Intravitreal injection of recombinant human MANF protein protects both rod and cone from degeneration."
I like this part, "There's also a massive human study going on." Huge implications.
Fair enough. I bet you're holding on to some now, too. Best of luck.
Thanks, Tanis. I had seen that. So many arrows in the quiver.
Given Dr. Stern's assertion that a diagnostic tool is the #1 priority for TBI that's how I see it. I really liked how Risk put it - getting the funding isn't the rocket science part of what's going on here.
Solantey,
No one here is that stupid. Today's news is about Lympro in TBI/CET. It has nothing to do with Lympro's timeline to market in AD. In fact, today's news substantially empowers AMBS in negotiations.
Wrap your mind around this:
http://www.bizjournals.com/bizjournals/how-to/growth-strategies/2014/01/concussions-epidemic-sports-profits.html
And also this: "Congrats to Dr Stern on the new contract w/ the Dept of Defense to study #TBI following concussions #SoMuchWorkToDo #mentalhealth #CTE #C4CT"
Geez. Just buy back in already.
The rest of my order from Tuesday filled on this dip. Good news for me. Also, if you're not seeing how good today's news is you are blind and perhaps beyond hope. The NIH is paying for the research that is putting AMBS in a much stronger negotiating position for Lympro. How is this bad?
Here's a great overview of TBI from UCSF: http://www.ucsf.edu/news/2013/10/109851/traumatic-brain-injury-research-advances-188-million-nih-award-administered-ucsf
Thanks. I honestly never built an understanding on the CET/TBI angle as I focused on AD, PD, and then more recently Wolfram's/Diabetes. Turns out CET/TBI is a big deal. If Lympro were to become a standard part of the diagnostic side of both AD and TBI it would be huge score. When AMBS first started working on Lympro I saw it as a way to get a little revenue for MANF study, but now I'm beginning to see there's a lot more going on here. I guess I'm late to the party on this. Geez, take MANF out of the picture and AMBS would still be in a very good position.
I'm still trying to get a handle on what's afoot with AMBS and CET/TBI. Here's a couple of articles that give some broader context of the researchers and the direction things are going:
First, the NIH/NFL grants - two each for $6million: http://www.nih.gov/news/health/dec2013/ninds-16.htm
Second, the BU work that apparently is using Lympro to screen patients and recipient of one of the 6mil grants: http://www.bu.edu/today/2014/med-researchers-to-share-6-million-nih-grant-for-cte/
Check out his other tweets from Sunday.
fibonacci ?@fibonacci1170 Jan 25
Alert: $AMBS to announce this week name of its flagship #LymPro science+business JV collaborator for Chronic Traumatic Encephalopathy (CTE).
Did anyone else see this tweet?
fibonacci ?@fibonacci1170 Jan 25
The Boston University Center for the Study of Traumatic Encephalopathy (BU CSTE) will use $AMBS #LymPro biomarker to screen CTE patients.
Thoughts?
True enough. I'm going to look at the bright side.
LOL
Man, the YMB is so full of stupid today that I just can't deal. I'm just glad JN got that tweet out.
I'm someone who likes to wade into the complexity and come out on the other side with a simple and supportable thesis. I've done that with the Lympro white paper and come up with this: currently, Lympro is first in class and in line to be first to market in a large and unaddressed market.
It's important to me to wade into the counter-argument with the same basic process. (Aside: If there is a better alternative than Lympro I'd like to know so I can invest in that instead. So if anyone can tell me let me know). But the argument against Lympro as far as I can discern is as follows...
Multiple choice:
1. There are better alternatives than Lympro. They are... ????
2. Just because there aren't better alternatives than Lympro doesn't mean Lympro will work. In fact, Lympro can't work. Because ???? science ???
3. Just because Lympro works and will get to market first no one will need it. Because it is a useless test based on market study ??? posted where ???
4. All of the above.
When I lay it out like that I can see with clarity that the argument against Lympro is incoherent. Whether deliberately incoherent and obfuscation, I don't know. It doesn't matter. What matters is there is no clear case being made.
Zoom. Thanks for reminding us what all the evidence points to, Lympro is first in class and will be first in market.
There's your buy over .09 by Gerald. Actions are speaking louder than words right now. Love it.
http://content.stockpr.com/sec/0001144204-14-002770/0001144204-14-002770.pdf
I can confirm that this is correct. I talked with IR today and they confirmed. Debentures not in play yet.
Talked with IR today and they checked with counsel. They were very prompt in calling me back. I was told that the warrants are not, as of yet, registered so today wasn't on the clock, so to speak. Couldn't say when it will be finalized but hopefully soon. Also, this week went very well and we should see some positive press soon.
Hi 61,
Sorry I took a name so close to yours. I had no idea.
Boom goes the dynamite. Thanks, again, Zoom. I thought I had this paper memorized but you nailed it.
The pros who sift the wheat from the chaff will begin entering. Big money on the way.
Thanks. Just trying to remain calm, stay wise, and let it unfold. Cheers.
You know, given all that's going on with AMBS right now, that we have a dated and irrelevant sticky on MJFF is goofy. Just my opinion.
Hello DocStock,
It's good to hear the perspective of someone who's been on this journey from way back. Thanks for sharing and make yourself at home here.
Leadership requires vision and execution. This company has had vision and the science to back it for some time now for anyone who has the nose to sniff such things. What we are witnessing over the past 13 months is a very clear picture of a company that knows how to execute a plan to implement a world class vision. Other than getting married, this is the biggest bet I've placed in my life and I'm glad I'm in for the ride. Looking forward to a whole new vista on life and it's opportunities.
All imho
Absolutely, that's exactly what I mean. The reason why they gather the quality of people they gather is because they have vision and the discipline to execute. I don't have the DD chops of some of you or a scientific background but I have had an opportunity to be around some history-altering people and watch how they function. Vision based on a tremendous truth or idea, and then the discipline and humility to execute a plan. AMBS has it and I am convinced we are in near the bottom floor of a life-changer.
See, that's what I love about the AMBS team. It's not just that they have solid science and a protein, it's that they act with vision and understand and work the angles. Remaining patient.
I am relatively young and have 100k shares in my Roth. If AMBS hits all the way to the big time that will be way more than enough. The rest of my shares are in my trading account. I am hoping to fund a non-profit enterprise I am starting.
Thanks. Overall I'm long for 550k shares with an entry point averaging in the .05's. I'm so overweight AMBS right now I'm pushing the boundaries. If all goes right in the next year I won't ever have to extend this far again.
Hey gipper, that's what I concluded, too. I had a few bits and pieces left that I could throw at it and bought a little more than 10,000 shares at .081.
About a month ago I was hoping we could form a base up around .07 or so before news hit. Now that it looks like .075 is pretty firm I'm hoping for something around .09 or even .10 as the new base. Not bad. Not bad at all.
In my opinion the risk here is almost all on the upside. News will take us well over .10 for good and can come at any time.
Yes. Very interesting. Thanks for sharing. Imagine if the next bit of news to hit wasn't for Lympro or MANF. AMBS has a deep bench.
Risk, this is how I see today's trading, too. As a long my preference would be for a nice solid launching base within shooting distance of .10. If we don't have to double the pps in order to cross the .10 threshold we will be in very good shape when the news release(s) come.
Question in light of Zoom's links:
Doesn't this indicate that it is safe to infer that AMBS is moving along on a plan to file an IND in late 2014 just as they have long stated is their goal?